Ingredient news
Korea's Choline Drug Market Faces Clawbacks After Reassessment Misses Endpoint
By Nutranexa News |
Korean choline alfoscerate drugs failed the primary endpoint in a clinical reassessment for mild cognitive impairment, putting reimbursement and clawback outcomes in focus.
Reassessment Result
Korean pharmaceutical companies submitted results last month from the first large-scale confirmatory domestic clinical trial of choline alfoscerate drugs for mild cognitive impairment, and the primary endpoint was not met.
The Ministry of Food and Drug Safety is reviewing the results, and the outcome will determine whether the indication is retained and how large health insurance clawbacks become.
Market Context
Choline drug prescriptions in Korea were 622.3 billion won in 2023, 612.3 billion won in 2024, and 545.6 billion won in 2025, according to market research firm UBIST.
The National Health Insurance Service signed conditional clawback contracts with manufacturers to recover 20% of prescription amounts from June 2021 if indications are deleted, and companies including Daewoong Bio and Chong Kun Dang have recognized estimated liabilities approaching 100 billion won each.
The report also notes that seven of Korea's eight drug-pricing reference countries treat choline products as food ingredients or health functional foods rather than reimbursed medicines.
Buyer Takeaway
For suppliers of choline and GPC-type ingredients, the Korean reassessment reinforces a global pattern where cognitive ingredients are shifting from pharmaceutical reimbursement toward supplement and food channels.
Buyers should watch the Korean market as a demand signal, while keeping in mind that the reassessment covers a pharmaceutical indication and does not address supplement-formulation rules.